However, APOE ε4 dosage and baseline cognitive function did not significantly modify the relationships of glucosamine use with incident vascular dementia or Alzheimer’s disease (All P-interactions > 0.05). The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.